CD274 and non-small cell lung carcinoma: Since then, several prospective trials have assessed the addition of a PD‐1/PD‐L1 to concurrent chemoradiotherapy (e.g., NCT03728556, NCT03519971, NCT03745222: RATIONALE001) or to SBRT (e.g., NCT03774732: NIRVANA‐Lung) in NSCLC patients.